Key result
Intravenous propafenone increased conversion to sinus rhythm compared to placebo in recent-onset paroxysmal atrial fibrillation (58.5% vs 29.4%; OR 3.2; 95% CI 1.3-7.9; p<0.01).
Why the study?
Does intravenous propafenone improve conversion to sinus rhythm in patients with paroxysmal atrial fibrillation of recent onset?
Population
75 patients, aged 18 to 70 years, with paroxysmal atrial fibrillation of recent onset. Exclusions: clinical…
Comparison
Intravenous propafenone vs Matching placebo
Design
RCT, Randomly allocated, Double-blind
Follow-up
3 h
Authors
Loading...
Supports IV propafenone for acute conversion in recent-onset paroxysmal AF; strengthens randomized evidence for clinical use.
RCT (n=75)
Double-blind
Randomly allocated
Yes
Does intravenous propafenone improve conversion to sinus rhythm in patients with paroxysmal atrial fibrillation of recent onset?
Odds Ratio: 3.2 (95% CI 1.3–7.9)
Absolute Event Rate: 58.5% vs 29.4%
p-value: p=< 0.01
Intravenous propafenone is highly effective for the rapid pharmacological conversion of recent-onset paroxysmal atrial fibrillation to sinus rhythm.
Fresco et al. (1996) conducted an RCT in Paroxysmal atrial fibrillation of recent onset (< 72 h) (n=75). Intravenous propafenone vs. Placebo was evaluated on Conversion to sinus rhythm (OR 3.2, 95% CI 1.3-7.9, p=< 0.01). Intravenous propafenone increased conversion to sinus rhythm compared to placebo in recent-onset paroxysmal atrial fibrillation (58.5% vs 29.4%; OR 3.2; 95% CI 1.3-7.9; p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: